glofitamab: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
glofitamab: clinical details
Prescribing considerations
- Treatment requires an experienced cancer specialist and immediate access to support for cytokine release syndrome and neurotoxicity.
- Use obinutuzumab pre-treatment, appropriate premedication and hydration as specified in the product protocol.
- Do not administer during an active infection; consider antimicrobial prophylaxis for patients at increased risk.
- Assess tumour burden, renal function and hydration when evaluating tumour lysis risk.
- Evaluate tumour flare risk where swelling could compromise vital structures.
- Avoid live vaccines during treatment and record the product name and batch number for traceability.
Contraindications and cautions
- Hypersensitivity to glofitamab, obinutuzumab or any product excipient.
Monitoring
- Monitor for cytokine release syndrome and infusion reactions during every infusion, with enhanced observation after initial treatment.
- Assess for confusion, altered consciousness, disorientation, aphasia, dysgraphia or seizures.
- Monitor full blood count and assess for infection, including opportunistic or reactivated infection.
- Check electrolytes, renal function, hydration and uric acid in patients at risk of tumour lysis syndrome.
- Check liver tests, particularly if cytokine release syndrome occurs.
- Monitor tumour sites for inflammatory flare, pain or swelling.
Clinical pharmacology
Glofitamab is a humanised IgG bispecific antibody targeting CD20 and CD3. It forms an immune synapse between B cells and T cells, causing T-cell activation and CD20-positive B-cell lysis. It is expected to be cleared mainly through protein catabolism.
Formulation and product differences
- Available as sterile concentrate in different vial presentations.
- All presentations require dilution before intravenous infusion and must not be given by intravenous push or bolus.
- The concentrate is a clear, colourless solution; cloudy, discoloured or particulate-containing vials must be discarded.
glofitamab preparations and strengths
Solution for infusion
Route: Intravenous
Strengths: 2.5 mg, 10 mg
glofitamab interactions
Formal interaction studies are limited. The treatment team should review all prescribed, non-prescribed and herbal products.
Warfarin, ciclosporin and other narrow-therapeutic-index CYP450 substrates
Early cytokine release may temporarily reduce CYP450 activity, potentially increasing exposure; additional monitoring may be needed when treatment starts.
Live vaccines
Live vaccination is not recommended during treatment because safety has not been established and immune function is affected.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.